Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.

Journal:

Diabetes Care

Published:

2025-07-30

DOI:

10.2337/dc25-0472

Affiliations:

14

Authors:

399

Go to article

Institutions	Authors	Share
Novo Nordisk, Denmark	4.000000	0.29
University Hospital of Erlangen, FAU, Germany	1.500000	0.11
University Hospitals Leuven (UZ Leuven), Belgium	1.000000	0.07
The University of Chicago Medicine, United States of America (USA)	1.000000	0.07
University of New South Wales (UNSW Sydney), Australia	1.000000	0.07
AdventHealth, United States of America (USA)	1.000000	0.07
Albany Medical Center, United States of America (USA)	1.000000	0.07
Stanford Medicine, United States of America (USA)	1.000000	0.07
University of Washington (UW), United States of America (USA)	0.500000	0.04
Providence Inland Northwest Health Services (INHS), United States of America (USA)	0.500000	0.04
Steno Diabetes Center Copenhagen (SDCC), Denmark	0.500000	0.04
KfH Kuratorium für Dialyse und Nierentransplantation e.V., Germany	0.500000	0.04
University of Copenhagen (UCPH), Denmark	0.500000	0.04

Interested in Clinical Sciences?